# FluoGuide

Source: https://onco.cc/companies/fluoguide/  
OnCo record `fluoguide` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FluoGuide makes an injected dye that makes cancer glow under near-infrared light during an operation, so surgeons can see what to remove. It is being tested in brain tumour surgery in the US.

## Summary

FluoGuide A/S, of Copenhagen, Denmark, is a clinical-stage company whose lead product FG001 is a near-infrared fluorescent imaging agent targeting uPAR, given intravenously before surgery to highlight tumour tissue. The company reports proof of concept in head and neck cancer, squamous non-small cell lung cancer and high-grade glioma, a collaboration with Intuitive Surgical on robotic-assisted head and neck surgery, work on using FG001 for photothermal therapy, and a SEK 60 million financing in 2024. Its US phase 2 trial (NCT07609472) tests a single dose of FG001 in 76 planned patients with newly diagnosed high-grade glioma, measuring tumour-to-background contrast and near-complete resection on MRI; the company enrolled its first patient in October 2026. Its shares were moving from Spotlight to Nasdaq First North in 2026. Its first registered study on ClinicalTrials.gov, NCT07609472, was posted in May 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: FluoGuide A/S
- HQ: Copenhagen
- Type: biotech
- Website: https://fluoguide.com/

## Notes

- Founding year not stated on the pages read on 29 October 2026; the site footer reads 2019 to 2026 and the Danish company number is CVR 39296438.
- Ticker not recorded because it was not read on a page fetched.
- Earlier FG001 trials in Denmark are not on ClinicalTrials.gov under this sponsor name and were not read.

## Sources

- Official website: https://fluoguide.com/
- Company history: https://fluoguide.com/about/history/
- First US phase 2 patient enrolled, October 2026: https://fluoguide.com/mfn_news/fluoguide-enrolls-first-patient-in-u-s-phase-2-trial-of-fg001-in-high-grade-glioma/
- ClinicalTrials.gov: phase 2 trial of FG001 in high-grade glioma (NCT07609472): https://clinicaltrials.gov/study/NCT07609472

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Surgery & Interventional](https://onco.cc/fronts/surgery/)
- technologies: [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/)

---
JSON: https://onco.cc/api/v1/entities/fluoguide.json